Blood and neoplastic diseases. Acute myeloblastic leukaemia.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001803:Blood Transfusion; D001815:Bloodletting; D002452:Cell Count; D003520:Cyclophosphamide / Q000627:therapeutic use; D003596:Cytosine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006087:Graft vs Host Reaction / Q000528:radiation effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D007962:Leukocytes / Q000528:radiation effects; D008017:Life Expectancy; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D003596:Cytosine; D003520:Cyclophosphamide; D011239:Prednisolone; D013866:Thioguanine; D011241:Prednisone; D003630:Daunorubicin